Xtreme Plays

[Arbel]

$EKNL, DROP – Diabetes Care and Treatment will be Top priority in 2013

Both core plays continue to hold solid to Monster gains and early indication in the first trading days of the New Year definitely is showing major action in the works and ready for a major breakout at any time.

We anticipate huge news in the coming days that will definitely stir major action and members definitely want to be in the game when it does.

Diabetes care specifically will be front and center for 2013 and the need for improvement in their healthcare across the country top priority.

“This clearly shows that the government needs to make diabetes a national priority and to insist that 2013 is the year when people with diabetes really start to notice their healthcare improving,” http://www.moneyexpert.com/financial-news/none/800581469/diabetescarenotimproving,revealscharitysurvey/article.aspx

With the upcoming OneMedForum SF 2013 conference in San Fransisco on Jan 7-9th http://www.onemedplace.com/forum, diabetes screening and treatment will definitely be a hot topic starting withhttp://www.neurometrix.com/Collateral/Images/Common/NC-stat-DPN-Check-device-with-numbers-v7-revised.jpg Neurometrix (NASDAQ:NURO)’s NC-Stat DPN check device which will be presented at the conference.

NeuroMetrix, Inc. (NAS: NURO) , www.neurometrix.com, a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the 6th Annual OneMedForum at the Sir Frances Drake Hotel, San Francisco, CA on January 7-9, 2013. Dr. Gozani intends to provide an update on the Company’s business activities and on its diabetes products including NC-stat® DPNCheck™, a diagnostic test for systemic neuropathies such as diabetic peripheral neuropathy (DPN), and the SENSUS™ pain management device for relief of chronic intractable pain. http://www.onemedplace.com/forum/6th-annual-onemedforum-presenting-companies

This will no doubt push the awareness of these NC-Stat DPN testing devices to an whole new level and “in the face” of USA Medical Professionals across the country – and no doubt increase awareness of EKNL/NCI diabetes treatment with their FDA approved FREMS technology.

With key monster news ready to be unleashed and key dates to keep close eye on, EKNL is definitely at super bargain levels with 500%+ gain potential towards our $2.00 price target!